Renal replacement therapy, an alternative for patient quality of life

Terapia de reemplazo renal, una alternativa para la calidad de vida de los pacientes

Chronic kidney disease is a condition caused by the loss of kidney function with impaired glomerular filtration for more than three months, making it necessary to receive renal replacement therapy which is a substitute for the normal function of kidneys by removing fluid from the blood using filtration across semipermeable membranes, especially to maintain homeostasis by removing toxic nitrogenous substances and accumulated wastes. These procedures, in particular hemodialysis, may lead to various complications for they are invasive processes. It is worth mentioning that replacement therapy may decrease patients´ quality of life, especially impacting their physical and psychological domains, at the expense of maintaining a better condition of their renal health.

1. C1. Cuevas-Budhart MA, Saucedo García RP, Romero Quechol G, García J, Hernández Paz y Puente A. Relación entre las complicaciones y la calidad de vida del paciente en hemodiálisis. Enferm Nefrol. 2017;20(2):112-119. https://dx.doi.org/10.4321/s2254-288420170000200003
2. Prakouraa N, Kavvadasa P, Chadjichristosa C. Connexin 43: a New Therapeutic Target Against Chronic Kidney Disease?. Cell Physiol Biochem. 2018;49(3):998-1009. doi: 10.1159/000493230
3. Dalas M, Vásquez A, Fernández Y, Guerra G. Comportamiento de factores pronósticos de morbilidad y mortalidad en una Unidad de Hemodiálisis. Rev Cubana Med. 2008;47(3):1-12.
4. Terazón MO, Vinent TMA, Pouyou SJ. Determinación del grado de enfermedad renal crónica en pacientes hipertensos. MediSan. 2017;21(1):19-26
5. Ko S, Venkatesan S, Nand K, Levidiotis V, Nelson C, Janus E. International statistical classification of diseases and related health problems coding underestimates the incidence and prevalence of acute kidney injury and chronic kidney disease in general medical patients. Intern Med J. 2018;48(3):310-315. doi: 10.1111/imj.13729
6. Castellanos Y, Fong J, Vázquez J, Fong J. Marcadores de daño renal en pacientes con factores de riesgo de enfermedad crónica. Medisan. 2018;22(2):142 -148.
7. Gutiérrez M, Polanco C. Enfermedad renal crónica en el adulto mayor. Rev Finlay. 2018;8(1):1-8
8. Nelveg-Kristensen KE, Hellmund G, Goya Heaf J. Risk of death after first-time blood stream infection in incident dialysis patients with specific consideration on vascular access and comorbidity. BMC Infect Dis. 2018;18(1):688. doi: 10.1186/s12879-018-3594-7
9. Bawazier LA, Suhardjono S. Comparison of Quality of Life between Patients Undergoing Chronic Hemodialysis with Reusable Dialyzer and Single-Use Dialyzer: A Retrospective Cohort Study. Acta Med Indones. 2018;50(3):222-229
10. Galindo P, Martínez T, Osuna A, Asensio C. Morbilidad en hemodiálisis. Nefrología. 2002;12(2):202-203
11. Kim H., Kim Y., Kim S., Chin H., Lee H., Lee J., et al. Age, sex, and the association of chronic kidney disease with all-cause mortality in Buddhist priests. Medicine. 2018;97(45):e13099. doi: 10.1097/MD.0000000000013099
12. Lopera M. La enfermedad renal crónica en Colombia: necesidades en salud y respuesta del Sistema General de Seguridad Social en Salud. Rev Gerenc Polít Salud. 2016;15(30):212-233. https://doi.org/10.11144/Javeriana.rgyps15-30.ercc
13. Semanat D., Fernandes M., Torres R., Sat F. El exceso de peso como un factor de riesgo de complicaciones durante la hemodiálisis iterada. RCAN. 2018;27(1):49-67.
14. Luxardo R, Kramer A, González-Bedat MC, Massy ZA, Jager KJ, Rosa-Diez G, et al. The epidemiology of renal replacement therapy in two different parts of the world: the Latin American Dialysis and Transplant Registry versus the European Renal Association- European Dialysis and Transplant Association Registry. Rev Panam Salud Publica. 2018;42:e87. doi: 10.26633/RPSP.2018.87
15. Kramer A, Pippias M, Noordzij M, Stel VS, Afentakis N, Ambühl PM, et al. The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. Clin Kidney J. 2018;11(1):108-122. doi: 10.1093/ckj/sfx149
16. Antlanger M, Noordzij M, van de Luijtgaarden M, Carrero JJ, Palsson R, Finne P, et al. Sex Differences in Kidney Replacement Therapy Initiation and Maintenance. Clin J Am Soc Nephrol. 2019;14(11):1616-1625. doi: 10.2215/CJN.04400419
17. Malta DC, Machado ÍE, Pereira CA, Figueiredo AW, Aguiar LK, Almeida WDS, et al. Evaluation of renal function in the Brazilian adult population, according to laboratory criteria from the National Health Survey. Rev Bras Epidemiol. 2019;22Suppl 02(Suppl 02):E190010.SUPL.2. doi: 10.1590/1980-549720190010.supl.2
18. Hu J, Du Y. Managing chronic kidney disease in diabetes patients with the latest chemical therapies. Expert Rev Clin Pharmacol. 2019;12(1):53-60. doi: 10.1080/17512433.2019.1552829
19. Li L, Tang W, Yi F. Role of Inflammasome in Chronic Kidney Disease. Adv Exp Med Biol. 2019;1165:407-421. doi: 10.1007/978-981-13-8871-2_19
20. Mun KH, Yu GI, Choi BY, Kim MK, Shin MH, Shin DH. Association of Dietary Potassium Intake with the Development of Chronic Kidney Disease and Renal Function in Patients with Mildly Decreased Kidney Function: The Korean Multi-Rural Communities Cohort Study. Med Sci Monit. 2019;25:1061-1070. doi: 10.12659/ MSM.913504
21. Gai Z, Wang T, Visentin M, Kullak-Ublick GA, Fu X, Wang Z. Lipid Accumulation and Chronic Kidney Disease. Nutrients. 2019;11(4). pii: E722 doi: 10.3390/nu11040722
22. Alhambra MR, Molina MJ, Olveira G, Arraiza C, Fernández M, García JM, et al. [Recommendations of the GARIN group for dietary managing of patient with chronic kidney disease]. Nutr Hosp. 2019;36(1):183-217. doi: 10.20960/nh.1823
23. Abd ElHafeez S, Hegazy R, Naga Y, Wahdan I, Sallam S. Non- steroidal anti-inflammatory drugs among chronic kidney disease patients: an epidemiological study. J Egypt Public Health Assoc. 2019;94(1):8. doi: 10.1186/s42506-018-0005-2
24. Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. Am J Kidney Dis. 2018;72(1):136-148. doi: 10.1053/j.ajkd.2017.11.021
25. Silva DMD, Silva RMCRA, Pereira ER, Ferreira HC, Alcantara VCG, Oliveira FDS. The body marked by the arteriovenous fistula: a phenomenological point of view. Rev Bras Enferm. 2018;71(6):2869-2875. doi: 10.1590/0034-7167-2017-0898
26. Merinoa JL, Domíngueza P, Buenoa B, Amézquitab Y, Espejoa B, Paraíso V. Aplicación de una pauta de hemodiálisis incremental, basada en la función renal residual, al inicio del tratamiento renal sustitutivo. Nefrología. 2017;37(1):39–46. https://dx.doi.org/10.1016/j.nefro.2016.11.015
27. Liew A. Perspectives in renal replacement therapy: Haemodialysis. Nephrology (Carlton). 2018; 23 Suppl 4:95-99. doi: 10.1111/nep.13449
28. Jameson J, Fauci A, Kasper D, Hauser S, Longo D, Loscalzo J. Harrison's Principles of Internal Medicine. 20ed. McGraw-Hill Education; 2018.
29. Connor M., Karakala N. Continuous Renal Replacement Therapy: Reviewing Current Best Practice to Provide High-Quality Extracorporeal Therapy to Critically Ill Patients. Adv Chronic Kidney Dis. 2017;24(4):213-218. doi: 10.1053/j.ackd.2017.05.003
30. Heung M., Yessayan L. Renal Replacement Therapy in Acute Kidney Injury: Controversies and Consensus. Crit Care Clin. 2017;33(2):365–378. doi: 10.1016/j.ccc.2016.12.003
31. Pun PH, Middleton JP. Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk. J Am Soc Nephrol. 2017;28(12):3441-3451. doi: 10.1681/ASN.2017060640
32. Mandel-Shorer N, Tzvi-Behr S, Harvey E, Revel-Vilk S. Central venous catheter-related venous thrombosis in children with end-stage renal disease undergoing hemodialysis. Thromb Res. 2018;172:150-157. doi: 10.1016/j.thromres.2018.10.031
33. Kraus MA, Kansal S, Copland M, Komenda P, Weinhandl ED, Bakris GL, et al. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis. 2016;68(5S1):S51-S58. doi: 10.1053/j.ajkd.2016.05.020
34. Lerma EV, Rosner MH, Perazella MA. CURRENT Diagnosis & Treatment: Nephrology & Hypertension. 2ed. New York: McGraw-Hill; 2018.
35. Himmelfarb J, Ikizler T. A. Chronic Kidney Disease, Dialysis, and Transplantation. 4Ed. Elsevier; 2019.
36. Song YH, Seo EH, Yoo YS, Jo YI. Phosphate supplementation for hypophosphatemia during continuous renal replacement therapy in adults. Ren Fail. 2019;41(1):72-79. doi: 10.1080/0886022X.2018.1561374
37. Cases A, Egocheaga M, Tranche S, Pallarés V, Ojeda R, Górriz J, et al. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología. Nefrología. 2018;38(1):8–12. doi: 10.1016/j.nefro.2017.09.004
38. Chen H, Zhang X, Shen X. Ocular changes during hemodialysis in patients with end-stage renal disease. BMC Ophthalmology. 2018;18(1):208. doi: 10.1186/s12886-018-0885-0
39. Rajoy G., Rionda M., Pérez C. Análisis de los factores que influyen en la aparición de complicaciones y supervivencia de los catéteres venosos centrales para hemodiálisis. Enferm Nefrol. 2014;17(1):1621. https://dx.doi.org/10.4321/S2254-28842014000100003
40. Fiterre I, Suárez C, Sarduy R, Castillo B, Gutiérrez F, Sabournin N, et al. Factores de riesgo asociados con sepsis del acceso vascular de pacientes en hemodiálisis. Rev haban cienc méd. 2018;17(2):335-346.
41. Gómez J, Pimienta L, Pino R, Hurtado M, Villaveces M. Prevalencia de infección asociada a catéter de hemodiálisis en el Hospital Universitario Clínica San Rafael. Rev. Colomb. Nefrol. 2018;5(1):17–25. https://doi.org/10.22265/acnef.5.2.283
42. Pérez Y, Sotolongo Y, Muradás M, Vigoa L, Lugo E. Supervivencia y complicaciones de los catéteres para hemodiálisis: nuestra experiencia. Rev Cubana Cir. 2006;45:3-4.
43. Crespo R, Contreras M, Casas R, Muñoz I, Moreno M, Suanes L. Estudio retrospectivo de las complicaciones de los catéteres temporales para hemodiálisis. Rev Soc Esp Enferm Nefrol. 2011;14(1):43-49.
44. Planche M, Suárez C, Frómeta V. Factores pronósticos de las complicaciones de las fístulas arteriovenosas autólogas para hemodiálisis. MediSan. 2016;20(4):1-8.
45. Ren C, Chen J, Wang Y, Huang B, Lu W, Cao Y, et al. Application of ultrasonography in monitoring the complications of autologous arteriovenous fistula in hemodialysis patients. Medicine. 2018;97(44): e12994. doi: 10.1097/MD.0000000000012994.
46. Sosa O. Fístulas arterio-venosas trombosadas para hemodiálisis y su tratamiento. Rev Haban Cienc Méd. 2017;18(2):192-201.
47. Lyu B, Banerjee T, Scialla J, Shafi T, Yevzlin A, Powe N, et al. Vascular Calcification Markers and Hemodialysis Vascular Access Complications. Am J Nephrol. 2018;48(5):330–338. doi: 10.1159/000493549
48. Hickson LJ, Rule AD, Thorsteinsdottir B, Shields RC, Porter IE, Fleming MD, et al. Predictors of early mortality and readmissions among dialysis patients undergoing lower extremity amputation. J Vasc Surg. 2018;68(5):1505-1516. doi: 10.1016/j.jvs.2018.03.408
49. Guney I, Solak Y, Atalay H, Yazici R, Altintepe L, Kara F, et al. Comparison of effects of automated peritoneal dialysis and continuous ambulatory peritoneal dialysis on health-related quality of life, sleep quality, and depression. Hemodial Int. 2010;14(4):515-22. doi: 10.1111/j.1542-4758.2010.00465.x
50. Fong E, Bargman JM, Chan CT. Cross-sectional comparison of quality of life and illness intrusiveness in patients who are treated with nocturnal home hemodialysis versus peritoneal dialysis. Clin J Am Soc Nephrol. 2007;2(6):1195-200. doi: 10.2215/ CJN.02260507
51. Kraus MA, Fluck RJ, Weinhandl ED, Kansal S, Copland M, Komenda P, et al. Intensive Hemodialysis and Health-Related Quality of Life. Am J Kidney Dis. 2016;68(5S1):S33-S42. doi: 10.1053/j.ajkd.2016.05.023
52. Rehman IU, Chan KG, Munib S, Lee LH, Khan TM. The association between CKD-associated pruritus and quality of life in patients undergoing hemodialysis in Pakistan: A STROBE complaint cross- sectional study. Medicine (Baltimore). 2019;98(36):e16812. doi: 10.1097/MD.0000000000016812
53. Turkmen K, Yazici R, Solak Y, Guney I, Altintepe L, Yeksan M, et al. Health-related qualıty of lıfe, sleep qualıty, and depressıon in peritoneal dialysis and hemodıalysıs patıents. Hemodial Int. 2012;16(2):198-206. doi: 10.1111/j.1542-4758.2011.00648.x